Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
(1) Sipuleucel-T (Provenge) is an active cellular immunotherapy (therapeutic vaccine) that is designed to stimulate the patient's T-cells to recognize and attack prostate cancer cells that express prostatic acid phosphatase (PAP) antigen. (2) Sipuleucel-T demonstrated a survival benefit in men with advanced androgen-independent prostate cancer (AIPC), although this preliminary finding requires confirmation in larger trials. (3) Mild to moderate myalgia, chills, fever, and tremor are the most commonly reported adverse events for patients receiving sipuleucel-T. These events generally resolve quickly. (4) More studies are needed to evaluate sipuleucel-T in the earlier stages of prostate cancer and in combination with conventional therapies.
McKarney
I
I
D002170:Canada; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy; D014020:Tissue Extracts / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome
D019496:Cancer Vaccines; D014020:Tissue Extracts